Navigation Links
King Pharmaceuticals Showcases Data From Pain Pipeline of Medicines Designed to Deter Common Methods of Non-Therapeutic Use
Date:6/25/2009

tinue to advance the development of its pipeline products as planned; dependence on the high cost and uncertainty of research, clinical trials, and other development activities involving products in which King has an interest; dependence on the unpredictability of the duration and results of the FDA's review of Investigational New Drug applications ("IND"), NDAs, and Abbreviated New Drug Applications ("ANDA") and/or the review of other regulatory agencies worldwide that relate to those projects; dependence on the availability and cost of raw materials; dependence on no material interruptions in supply by contract manufacturers of King's products; dependence on King's compliance with FDA and other government regulations that relate to the Company's business; dependence on changes in general economic and business conditions; changes in current pricing levels; changes in federal and state laws and regulations; changes in competition; unexpected changes in technologies and technological advances; and manufacturing capacity constraints. Other important factors that may cause actual results to differ materially from the forward-looking statements are discussed in the "Risk Factors" section and other sections of King's Annual Report on Form 10-K for the year ended December 31, 2008 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2009, each of which is on file with the U.S. Securities and Exchange Commission. King does not undertake to publicly update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.


'/>"/>
SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... NEW YORK , May 1, 2015  Shares ... over 70% of their value yesterday following the results ... company,s glaucoma therapy, Rhopressa.  Despite the trial failing to ... indicates that positive results may come from future studies. ... a brief company overview, current pipeline, financial review, analyst ...
(Date:4/30/2015)... 30, 2015 Omnicell, Inc. (NASDAQ: OMCL ), ... to healthcare systems, today announced results for its first ... Revenue for the first quarter of 2015 was $116.2 ... quarter of 2014, and down $5.3 million or 4.4% ... quarter 2015 net income as reported in accordance with ...
(Date:4/30/2015)... Diabetes Care ® , Inc. (NASDAQ: TNDM ), a ... and t:flex™ Insulin Pumps, today reported its financial results for ... comparing the first quarter of 2015 to the same period ... million from $8.1 million , t:slim Pump shipments grew ... "Our investment in resources to build the foundation of our ...
Breaking Medicine Technology:All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2Omnicell Announces First Quarter 2015 Results 2Omnicell Announces First Quarter 2015 Results 3Omnicell Announces First Quarter 2015 Results 4Omnicell Announces First Quarter 2015 Results 5Omnicell Announces First Quarter 2015 Results 6Omnicell Announces First Quarter 2015 Results 7Omnicell Announces First Quarter 2015 Results 8Omnicell Announces First Quarter 2015 Results 9Omnicell Announces First Quarter 2015 Results 10Omnicell Announces First Quarter 2015 Results 11Omnicell Announces First Quarter 2015 Results 12Omnicell Announces First Quarter 2015 Results 13Omnicell Announces First Quarter 2015 Results 14Omnicell Announces First Quarter 2015 Results 15Omnicell Announces First Quarter 2015 Results 16Omnicell Announces First Quarter 2015 Results 17Omnicell Announces First Quarter 2015 Results 18Omnicell Announces First Quarter 2015 Results 19Omnicell Announces First Quarter 2015 Results 20Omnicell Announces First Quarter 2015 Results 21Omnicell Announces First Quarter 2015 Results 22Omnicell Announces First Quarter 2015 Results 23Omnicell Announces First Quarter 2015 Results 24Omnicell Announces First Quarter 2015 Results 25Omnicell Announces First Quarter 2015 Results 26Omnicell Announces First Quarter 2015 Results 27Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6
... Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) today announced ... the Jefferies 2012 Global Healthcare Conference in New York, NY. ... Presentation date: Monday, June 4, 2012 , Presentation time: 12:30 ... 30-day archive of these presentations will be available at http://ir.avanir.com ...
... - Hospital Universitari Vall d,Hebron Research Institute in Barcelona ... an open label phase 2 study evaluating the overall ... treatment of cirrhosis of the liver and upper GI ... patients demonstrated that OCR-002 is well tolerated and provided ...
Cached Medicine Technology:Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 2Preliminary Phase 2 Data of Ocera Therapeutics' OCR-002 for the Treatment of Liver Cirrhosis and Upper GI Bleeding Show Potent Ammonia Reduction 3
(Date:5/2/2015)... May 02, 2015 “ Peachtree Audio ... monthly Tech Report, which features the latest and coolest ... expert and special reporter for NewsWatch, conducted the review ... audio equipment. , Music is an important part ... be pampered and given the royal treatment. Peachtree Audio ...
(Date:5/2/2015)... (PRWEB) May 02, 2015 ZoomCare, the ... has submitted plans to offer its new healthcare insurance ... The ZOOM+ Personal Health Insurance System is the nation’s ... to enhance human performance. ZOOM+ Personal Health Insurance was ... delivery system that are subject to review and regulation ...
(Date:5/1/2015)... Pioneer Millworks, the largest reclaimed wood ... their reclaimed wood products at the 27th annual International ... in NYC this May. Their newest offerings, Vat 35, ... texture and color to North America's platform for global ... and color in the design world and we're excited ...
(Date:5/1/2015)... Costa Mesa, CA (PRWEB) May 01, 2015 ... sponsor at the Cerner Southeast Regional User Group (RUG) ... 2015. The Cerner Southeast Regional User Group Conference provides ... access to vendors who support all aspects of electronic ... innovative use of Cerner software applications. , In addition ...
(Date:5/1/2015)... Yorba Linda, CA (PRWEB) May 01, 2015 ... of our genetic makeup and the interplay of genes ... Keeping up with developments can be daunting. , LabRoots, ... sciences and clinical diagnostics professionals, will soon host its ... Genomics. , At BioConference Live Genetics and Genomics ...
Breaking Medicine News(10 mins):Health News:Affordable High-End Audio Equipment was Featured on NewsWatch Television 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 2Health News:Intensely Textured Reclaimed Wood to be Unveiled at ICFF in NYC by Pioneer Millworks 3Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner Southeast Regional User Group Conference 3Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 2Health News:Recent Advances in Genetics and Genomics: A BioConference Live 2015 Virtual Event 3
... 50 years medical research has been vetted through the ... reviewers to determine whether work merits publication. A study ... and their influence on journal editors who are the ... not. "Published research is becoming a more ...
... Small study found technique restored some muscle function for months ... in using gene therapy to restore some muscle function in ... is the first time such a feat has been performed ... at the annual meeting of the American Society of Gene ...
... Poorman or ... ... personality Jim “Poorman” Trenton has the wavefront Lasik procedure with Los Angeles Lasik ... most noted for his work on Loveline the nightly radio talk show on KROQ, which ...
... ... visibility at the management and board level , ... MetricStream, Inc., the market leader in enterprise-wide Governance, ... with AEI, an emerging markets energy infrastructure company, to provide MetricStream’s GRC Platform and ...
... program reduced cardiovascular disease-related medical and hospital costs, ... national company with 30,000 employees, developed the program ... cardiovascular disease when compared to national benchmarks and ... time, the program included a variety of interventions, ...
... for these two diseases? Or does diabetes cause processes in the ... still unclear why diabetics have a higher rate of cancer than ... In order to precisely identify the types of cancer in ... colleagues in Sweden and the United States to carry out the ...
Cached Medicine News:Health News:To publish or not to publish? That is the question 2Health News:Gene Therapy Shows Promise for Muscular Dystrophy 2Health News:Gene Therapy Shows Promise for Muscular Dystrophy 3Health News:'Poorman' Has Lasik with Dr. Khanna 2Health News:MetricStream Enters into Agreement to Provide Enterprise Risk Management Software Solution to AEI 2Health News:Increased cancer risk of people with type 2 diabetes 2
Taper with blunt tip. Stainless steel. Round knurled handle with polished finish. Taper : Medium 23 mm. Overall length: 3.9 inches....
Size 2 dilator. Stainless steel. Round knurled handle with polished finish. Overall length: 4 inches....
The interface spatula can be used when irregular interface adherence occurs. By beginning at the point of a dissected edge and sweeping in uniplanar motion towards the area of adherence, the flap can...
Duckbilled spatula designed to enter a side-port stab incision with tip broad enough to efficiently manipulate the lens nucleus in the anterior chamber. Spatula is useful for rotating and cracking th...
Medicine Products: